

Supplementary Documents [IFRS]
Financial results for the fiscal year 2025 (FY2025)
Astellas Pharma Inc.

- FY2025 Financial Results
 - For the year ended March 31, 2026
 - Three months ended March 31, 2026
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[For the year ended March 31, 2026]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue	1,912.3	2,139.2	226.9	11.9%
Cost of sales	349.2	408.4	59.2	17.0%
Gross profit	1,563.1	1,730.8	167.7	10.7%
SG&A expenses	843.0	860.3	17.3	2.0%
XTANDI co-promotion fee in the United States	252.6	248.2	-4.3	-1.7%
SG&A excl. the above	590.5	612.1	21.6	3.7%
Ratio to Revenue	30.9%	28.6%		
R&D expenses	327.7	314.8	-12.8	-3.9%
Ratio to Revenue	17.1%	14.7%		
Amortisation of intangible assets	136.8	136.0	-0.8	-0.6%
Gain on divestiture of intangible assets	1.0	4.3	3.3	314.6%
Share of profit (loss) of investments accounted for using equity method	-0.3	-1.8	-1.5	-
Other income	20.3	32.8	12.5	61.2%
Net foreign exchange gains	-	4.9	4.9	-
Fair value remeasurements on contingent consideration	16.7	16.9	0.3	1.7%
Other expenses	235.8	72.4	-163.3	-69.3%
Impairment losses for intangible assets	187.6	52.8	-134.8	-71.9%
Restructuring costs	15.5	9.9	-5.6	-36.1%
Net foreign exchange losses	18.6	-	-18.6	-
Operating profit	41.0	382.6	341.6	832.4%
Ratio to Revenue	2.1%	17.9%		
Finance income	7.9	8.0	0.2	1.9%
Finance expenses	17.7	14.1	-3.6	-20.4%
Profit before tax	31.2	376.6	345.4	-
Income tax expense	-19.5	85.0	104.5	-
Profit	50.7	291.6	240.8	474.6%
Comprehensive income	48.9	449.5	400.6	819.4%

Forecasts		Change from FY25
FY26 Full Year	Change (%)	
2,220.0	3.8%	
445.0	9.0%	
1,775.0	2.6%	
800.0	-7.0%	
216.0	-13.0%	
584.0	-4.6%	
26.3%		
355.0	12.8%	
16.0%		
395.0	3.2%	
17.8%		
385.0	2.2%	
300.0	2.9%	

2. Consolidated Results (Core Basis)

Unit: B¥

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue	1,912.3	2,139.2	226.9	11.9%
Cost of sales	349.2	408.4	59.2	17.0%
Gross profit	1,563.1	1,730.8	167.7	10.7%
SG&A expenses	843.0	860.3	17.3	2.0%
XTANDI co-promotion fee in the United States	252.6	248.2	-4.3	-1.7%
SG&A excl. the above	590.5	612.1	21.6	3.7%
Ratio to Revenue	30.9%	28.6%		
R&D expenses	327.7	314.8	-12.8	-3.9%
Ratio to Revenue	17.1%	14.7%		
Operating profit	392.4	555.7	163.2	41.6%
Ratio to Revenue	20.5%	26.0%		
Finance income	7.9	8.0	0.2	1.9%
Finance expenses	17.7	14.1	-3.6	-20.4%
Profit before tax	382.6	549.6	167.0	43.6%
Income tax expense	87.0	125.2	38.3	44.0%
Profit	295.7	424.4	128.7	43.5%

Forecasts		Change from FY25
FY26 Full Year	Change (%)	
2,220.0	3.8%	
445.0	9.0%	
1,775.0	2.6%	
800.0	-7.0%	
216.0	-13.0%	
584.0	-4.6%	
26.3%		
355.0	12.8%	
16.0%		
620.0	11.6%	
27.9%		
460.0	8.4%	

3. Exchange Rate

Unit: ¥

	FY24 Ave.	FY25 Ave.	FY24 End	FY25 End
USD/Yen	152	151	150	159
EUR/Yen	164	175	162	183

Forecasts
FY26 Full Year
150
180

* Fx impacts: Revenue +30.1 billion yen and Core operating profit +16.8 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY24 Full year			FY25 Full year		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	1,912.3	-	1,912.3	2,139.2	-	2,139.2
Cost of sales	349.2	-	349.2	408.4	-	408.4
Gross profit	1,563.1	-	1,563.1	1,730.8	-	1,730.8
SG&A expenses	843.0	-	843.0	860.3	-	860.3
R&D expenses	327.7	-	327.7	314.8	-	314.8
Amortisation of intangible assets *	136.8	-136.8	-	136.0	-136.0	-
Gain on divestiture of intangible assets *	1.0	-1.0	-	4.3	-4.3	-
Share of profit (loss) of investments accounted for using equity method *	-0.3	0.3	-	-1.8	1.8	-
Other income *	20.3	-20.3	-	32.8	-32.8	-
Other expenses *	235.8	-235.8	-	72.4	-72.4	-
Operating profit	41.0	351.4	392.4	382.6	173.0	555.7
Finance income	7.9	-	7.9	8.0	-	8.0
Finance expenses	17.7	-	17.7	14.1	-	14.1
Profit before tax	31.2	351.4	382.6	376.6	173.0	549.6
Income tax expense	-19.5	106.5	87.0	85.0	40.2	125.2
Profit	50.7	244.9	295.7	291.6	132.8	424.4

* 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets', 'Share of profit (loss) of investments accounted for using equity method', 'Other income' and 'Other expenses' are excluded from Core basis results. "Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

		FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue		1,912.3	2,139.2	226.9	11.9%
	United States	866.4	940.2	73.8	8.5%
	Ratio to Revenue	45.3%	44.0%		
	Japan	267.0	289.0	22.0	8.2%
	Ratio to Revenue	14.0%	13.5%		
	Established Markets	485.4	563.6	78.2	16.1%
	Ratio to Revenue	25.4%	26.3%		
	China	78.3	101.5	23.2	29.6%
	Ratio to Revenue	4.1%	4.7%		
	International Markets	203.5	230.7	27.2	13.4%
	Ratio to Revenue	10.6%	10.8%		

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

6. Per Share Information

	FY24 Full Year	FY25 Full Year
The number of shares issued (thousand)	1,809,663	1,809,663
Treasury Shares (thousand)	19,353	18,170
The number of shares issued after deducting Treasury Shares (thousand)	1,790,309	1,791,492
Earnings per share (yen)	28.35	162.77
Earnings per share (yen) core basis	165.17	237.01
Dividend per share (yen)	74	78
Return on Equity (%)	3.3%	17.4%
Dividend on Equity (%)	8.5%	8.4%

- The numbers of shares are presented by disregarding any number of shares less than the specified units.

Forecasts

FY26 Full Year

167.5
256.8
80.0

7. Investment in Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Investment in Property, Plant and Equipment	47.8	49.3	1.5	3.1%
Depreciation (PP&E)	44.9	43.6	-1.3	-2.8%
Amortisation of Intangible Assets (incl. software, etc.)	154.2	151.0	-3.3	-2.1%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

Forecasts Change from
FY25

FY26 Full Year	Change (%)
55.0	11.5%
45.0	3.1%
155.0	2.7%

8. Sales of major products

1) Global

Unit: B¥

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Strategic Brands Total	336.4	480.3	143.9	42.8%
PADCEV	164.1	221.2	57.1	34.8%
United States	109.1	129.2	20.0	18.4%
Japan	12.6	20.3	7.7	61.3%
Established Markets	32.7	52.2	19.5	59.5%
China	3.9	9.8	6.0	154.4%
International Markets	5.7	9.6	3.9	68.1%
IZERVAY	58.3	77.6	19.3	33.2%
United States	58.3	77.5	19.3	33.0%
Japan	-	0.1	0.1	-
VYLOY	12.2	63.1	50.9	415.6%
United States	4.9	29.9	25.0	514.2%
Japan	5.2	13.7	8.5	164.5%
Established Markets	2.2	11.3	9.1	417.3%
China	-	6.7	6.7	-
International Markets	-	1.5	1.5	-
VEOZAH	33.8	46.6	12.8	37.7%
United States	30.8	40.6	9.8	31.9%
Established Markets	2.7	4.8	2.1	76.3%
International Markets	0.3	1.1	0.8	257.4%
XOSPATA	68.0	71.8	3.9	5.7%
United States	35.0	32.0	-3.1	-8.8%
Japan	4.7	5.0	0.3	7.0%
Established Markets	18.9	23.0	4.2	22.2%
China	3.9	4.6	0.7	18.5%
International Markets	5.5	7.2	1.7	30.8%
XTANDI	912.3	960.8	48.5	5.3%
United States	491.7	483.7	-7.9	-1.6%
Japan	57.9	64.8	6.9	11.9%
Established Markets	262.1	291.0	29.0	11.1%
China	16.3	24.7	8.4	51.4%
International Markets	84.3	96.5	12.2	14.5%
BETANIS/MYRBETRIQ/BETMIGA	170.0	189.7	19.7	11.6%
PROGRAF	201.0	207.7	6.7	3.3%

Forecasts	Change from FY25
FY26 Full Year	Change (%)
610.0	27.0%

910.0	-5.3%
-------	-------

180.0	-5.1%
-------	-------

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by Region

(1) United States

Unit: M\$

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue	5,683	6,236	553	9.7%
PADCEV	716	857	141	19.7%
IZERVAY	382	514	132	34.5%
VYLOY	32	198	166	521.1%
VEOZAH	202	269	67	33.3%
XOSPATA	230	212	-18	-7.7%
XTANDI	3,225	3,209	-17	-0.5%
MYRBETRIQ	410	480	70	17.1%
CRESEMBA	310	362	52	16.9%

(2) Japan

Unit: B¥

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue	267.0	289.0	22.0	8.2%
PADCEV	12.6	20.3	7.7	61.3%
IZERVAY	-	0.1	0.1	-
VYLOY	5.2	13.7	8.5	164.5%
XOSPATA	4.7	5.0	0.3	7.0%
XTANDI	57.9	64.8	6.9	11.9%
BETANIS	24.6	22.3	-2.3	-9.5%
PROGRAF (Including GRACEPTOR)	21.2	18.2	-3.0	-14.1%
SUGLAT [Family]	26.4	23.3	-3.1	-11.9%
BLINCYTO	13.4	15.8	2.4	18.0%
EVENITY	57.9	74.2	16.3	28.2%

(3) Established Markets

Unit: M€

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue	2,967	3,224	257	8.7%
PADCEV	200	299	99	49.3%
VYLOY	13	64	51	384.1%
VEOZA	17	27	11	65.0%
XOSPATA	115	132	17	14.3%
XTANDI	1,602	1,665	63	3.9%
BETMIGA	382	419	37	9.7%
PROGRAF	459	459	0	0.0%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue	78.3	101.5	23.2	29.6%
PADCEV	3.9	9.8	6.0	154.4%
VYLOY	-	6.7	6.7	-
XOSPATA	3.9	4.6	0.7	18.5%
XTANDI	16.3	24.7	8.4	51.4%
PROGRAF	43.0	44.6	1.6	3.6%

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY24 Full Year	FY25 Full Year	Change	Change (%)
Revenue	203.5	230.7	27.2	13.4%
PADCEV	5.7	9.6	3.9	68.1%
VYLOY	-	1.5	1.5	-
VEOZA	0.3	1.1	0.8	257.4%
XOSPATA	5.5	7.2	1.7	30.8%
XTANDI	84.3	96.5	12.2	14.5%
BETMIGA	18.8	20.9	2.1	11.0%
PROGRAF	51.4	55.0	3.5	6.9%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

9. Consolidated statements of financial position

Unit: B¥

	FY24 End	FY25 End	Change
Assets	3,339.5	3,567.0	227.5
Non-current assets	2,138.2	2,145.1	6.9
Property, plant and equipment	328.9	358.4	29.5
Goodwill	415.2	441.2	26.0
Intangible assets	1,123.7	996.9	-126.8
Investments accounted for using equity method	19.0	20.3	1.3
Deferred tax assets	98.1	146.6	48.5
Other financial assets	124.6	138.3	13.6
Other non-current assets	28.6	43.4	14.8
Current assets	1,201.3	1,421.9	220.6
Inventories	297.3	331.0	33.8
Trade and other receivables	632.5	746.8	114.3
Income tax receivable	13.7	15.0	1.3
Other financial assets	29.9	9.6	-20.4
Other current assets	39.2	38.0	-1.2
Cash and cash equivalents	188.4	281.6	93.2
Assets held for sale	0.4	-	-0.4

Unit: B¥

	FY24 End	FY25 End	Change
Equity and Liabilities	3,339.5	3,567.0	227.5
Equity	1,513.3	1,830.9	317.6
Equity attributable to owners of the parent	1,513.3	1,829.0	315.8
Share capital	103.0	103.0	-
Capital surplus	185.3	185.2	-0.1
Treasury shares	-37.5	-34.9	2.6
Retained earnings	740.9	902.8	161.9
Other components of equity	521.6	673.0	151.4
Non-controlling interest	-	1.8	1.8
Liabilities	1,826.3	1,736.2	-90.1
Non-current liabilities	764.7	517.8	-246.9
Bonds and borrowings	564.9	320.0	-244.9
Income tax payable	3.2	6.7	3.5
Deferred tax liabilities	5.4	1.3	-4.1
Retirement benefit liabilities	22.7	21.5	-1.3
Provisions	8.1	8.2	0.1
Other financial liabilities	106.8	89.1	-17.7
Other non-current liabilities	53.6	71.0	17.4
Current liabilities	1,061.6	1,218.4	156.8
Bonds and borrowings	266.5	246.0	-20.6
Trade and other payables	187.8	199.8	11.9
Income tax payable	34.5	68.9	34.4
Provisions	17.3	23.5	6.3
Refund liabilities	348.0	422.6	74.5
Other financial liabilities	20.1	22.3	2.2
Other current liabilities	187.2	235.3	48.1

10. Employees

Number of employees

	FY24 End	FY25 End
Total	13,643	14,099

11. Shareholders

	FY24 End	FY25 End
Banks	36.3%	34.7%
Securities	7.3%	7.0%
Other companies	2.5%	2.1%
Foreign companies	38.6%	42.9%
Individuals and others	15.3%	13.3%
Treasury Stock*	0.0%	0.0%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

[Three months ended March 31, 2026]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY25							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	505.8	6.9%	524.3	13.4%	571.2	10.4%	537.9	17.1%
Cost of sales	94.8	4.1%	105.5	27.6%	114.4	16.1%	93.7	21.9%
Gross profit	411.0	7.6%	418.8	10.3%	456.8	9.1%	444.3	16.2%
SG&A expenses	197.0	-4.8%	206.8	3.7%	221.8	-1.6%	234.7	11.1%
XTANDI co-promotion fee in the United States	62.9	2.1%	64.3	-0.3%	65.9	-11.1%	55.2	5.1%
SG&A excl. the above	134.1	-7.7%	142.6	5.5%	155.9	3.1%	179.5	13.0%
Ratio to Revenue	26.5%		27.2%		27.3%		33.4%	
R&D expenses	71.7	-17.4%	71.6	-16.3%	75.6	-4.4%	95.9	25.9%
Ratio to Revenue	14.2%		13.7%		13.2%		17.8%	
Amortisation of intangible assets	32.8	-6.4%	32.7	-4.4%	34.7	-0.7%	35.8	9.8%
Gain on divestiture of intangible assets	3.7	306.9%	0.3	-	0.0	-94.1%	0.3	492.4%
Share of profit (loss) of investments accounted for using equity method	-1.6	-	0.0	-	-0.0	-	-0.1	-
Other income	4.4	-10.8%	0.8	-	20.2	-	7.4	-53.6%
Net foreign exchange gains	-	-	0.5	-	7.1	-	-2.7	-
Fair value remeasurements on contingent consideration	4.0	97.7%	0.0	-93.2%	12.8	-	0.1	-99.6%
Other expenses	21.3	105.5%	4.0	-75.6%	10.4	-94.6%	36.7	142.0%
Impairment losses for intangible assets	13.6	-	2.8	-	6.3	-96.5%	30.2	367.3%
Restructuring costs	2.8	8.7%	2.1	-59.9%	1.6	-35.9%	3.4	-34.0%
Net foreign exchange losses	2.3	-	-2.3	-	-	-	-	-
Operating profit	94.6	86.8%	104.7	143.3%	134.5	-	48.8	-23.2%
Ratio to Revenue	18.7%		20.0%		23.5%		9.1%	
Finance income	1.7	-61.5%	2.2	297.5%	1.9	-7.7%	2.3	145.4%
Finance expenses	5.9	31.2%	2.7	-46.6%	2.4	-42.1%	3.0	-22.3%
Profit before tax	90.4	79.1%	104.2	170.3%	134.0	-	48.0	-20.7%
Income tax expense	22.0	70.6%	25.0	846.6%	33.6	-	4.4	-
Profit	68.4	82.0%	79.2	120.6%	100.3	-	43.6	-41.8%
Comprehensive income	34.9	-76.7%	129.7	-	219.6	652.1%	65.3	256.7%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY25							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	505.8	6.9%	524.3	13.4%	571.2	10.4%	537.9	17.1%
Cost of sales	94.8	4.1%	105.5	27.6%	114.4	16.1%	93.7	21.9%
Gross profit	411.0	7.6%	418.8	10.3%	456.8	9.1%	444.3	16.2%
SG&A expenses	197.0	-4.8%	206.8	3.7%	221.8	-1.6%	234.7	11.1%
XTANDI co-promotion fee in the United States	62.9	2.1%	64.3	-0.3%	65.9	-11.1%	55.2	5.1%
SG&A excl. the above	134.1	-7.7%	142.6	5.5%	155.9	3.1%	179.5	13.0%
Ratio to Revenue	26.5%		27.2%		27.3%		33.4%	
R&D expenses	71.7	-17.4%	71.6	-16.3%	75.6	-4.4%	95.9	25.9%
Ratio to Revenue	14.2%		13.7%		13.2%		17.8%	
Operating profit	142.3	61.1%	140.4	48.1%	159.4	39.3%	113.6	19.7%
Ratio to Revenue	28.1%		26.8%		27.9%		21.1%	
Finance income	1.7	-61.5%	2.2	297.5%	1.9	-7.7%	2.3	145.4%
Finance expenses	5.9	31.2%	2.7	-46.6%	2.4	-42.1%	3.0	-22.3%
Profit before tax	138.0	56.6%	139.8	54.9%	158.9	41.5%	112.9	22.8%
Income tax expense	33.3	58.8%	33.1	98.7%	38.7	29.0%	20.1	4.2%
Profit	104.7	56.0%	106.7	45.0%	120.2	46.0%	92.8	27.8%

3. Revenue by Region

Unit: B¥

		FY25							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		505.8	6.9%	524.3	13.4%	571.2	10.4%	537.9	17.1%
	United States	224.7	6.0%	232.4	12.2%	243.5	-0.9%	239.5	19.0%
	Ratio to Revenue	44.4%		44.3%		42.6%		44.5%	
	Japan	68.9	3.4%	74.0	10.7%	80.1	11.0%	65.9	7.6%
	Ratio to Revenue	13.6%		14.1%		14.0%		12.3%	
	Established Markets	128.8	6.4%	136.1	14.4%	153.1	23.7%	145.6	19.7%
	Ratio to Revenue	25.5%		26.0%		26.8%		27.1%	
	China	29.4	57.8%	20.3	6.8%	27.6	35.6%	24.1	19.0%
	Ratio to Revenue	5.8%		3.9%		4.8%		4.5%	
	International Markets	53.2	2.3%	58.3	21.5%	63.2	21.1%	56.0	9.2%
	Ratio to Revenue	10.5%		11.1%		11.1%		10.4%	

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

4. Investment in Property, Plant and Equipment

Unit: B¥

Depreciation/Amortisation		FY25							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Investment in Property, Plant and Equipment		4.8	-64.1%	12.1	-20.2%	15.5	21.2%	16.8	165.9%
Depreciation (PP&E)		11.1	2.2%	10.7	-6.3%	10.7	-7.9%	11.1	1.3%
Amortisation of Intangible Assets (incl. software, etc.)		36.7	-6.9%	36.6	-5.2%	38.4	-2.8%	39.2	6.9%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit:BY

		FY25							
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Strategic Brands Total		112.1	48.7%	108.4	37.2%	132.6	48.2%	127.2	37.5%
PADCEV		55.5	44.6%	46.9	26.9%	60.1	44.6%	58.6	24.5%
	United States	31.7	16.7%	28.7	10.4%	30.8	12.6%	38.0	32.6%
	Japan	5.1	102.3%	5.0	107.8%	5.7	52.5%	4.5	14.5%
	Established Markets	9.5	26.1%	10.6	42.3%	18.6	115.4%	13.5	48.4%
	China	7.4	-	-0.2	-	2.3	-	0.3	-92.2%
	International Markets	1.8	62.6%	2.8	171.8%	2.7	54.1%	2.3	25.4%
IZERVAY		15.9	25.2%	18.2	18.3%	21.7	32.7%	21.8	57.6%
	United States	15.9	25.2%	18.2	18.3%	21.6	32.6%	21.7	57.2%
	Japan	-	-	-	-	0.0	-	0.1	-
VYLOY		14.0	-	12.5	-	19.5	425.6%	17.0	133.4%
	United States	5.9	-	6.3	-	8.8	664.0%	8.9	139.4%
	Japan	3.1	791.2%	3.3	274.4%	4.0	114.4%	3.3	58.0%
	Established Markets	1.7	-	2.7	-	3.3	390.5%	3.6	142.4%
	China	3.3	-	-0.1	-	2.9	-	0.6	-
	International Markets	0.1	-	0.3	-	0.5	-	0.6	-
VEOZAH		9.6	45.6%	13.3	62.0%	12.3	27.7%	11.4	21.2%
	United States	8.6	39.7%	11.9	59.2%	10.6	22.2%	9.6	12.2%
	Established Markets	0.9	107.2%	1.2	69.4%	1.3	46.5%	1.4	102.6%
	International Markets	0.1	861.7%	0.2	366.6%	0.3	258.9%	0.4	158.2%
XOSPATA		17.0	-1.9%	17.5	-0.3%	19.0	4.3%	18.3	23.1%
	United States	7.4	-17.8%	7.9	-10.5%	8.8	-8.0%	7.9	2.8%
	Japan	1.3	3.8%	1.2	7.2%	1.5	14.9%	1.0	1.1%
	Established Markets	5.6	20.8%	5.8	29.7%	5.4	17.4%	6.2	21.0%
	China	1.0	-26.6%	1.0	-41.3%	1.4	-11.0%	1.2	-
	International Markets	1.7	57.0%	1.5	9.0%	2.0	55.8%	1.9	12.8%
XTANDI		233.0	3.9%	244.0	7.3%	255.2	1.5%	228.5	9.2%
	United States	122.6	2.4%	125.2	-0.1%	129.0	-10.5%	106.9	4.5%
	Japan	15.9	7.1%	16.2	16.6%	17.7	13.7%	15.0	10.1%
	Established Markets	69.5	5.7%	71.8	8.8%	75.9	14.4%	73.8	15.3%
	China	4.8	58.3%	5.9	53.4%	6.6	55.4%	7.4	42.5%
	International Markets	20.2	-3.2%	24.8	35.9%	26.1	23.4%	25.4	5.6%
BETANIS/MYRBETRIQ/BETMIGA		43.0	-6.8%	43.5	38.4%	46.0	-2.0%	57.2	25.6%
PROGRAF		51.2	-4.9%	52.0	3.9%	55.6	7.6%	48.9	7.7%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by Region

(1) United States

Unit:M\$

		FY25							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		1,555	14.3%	1,576	13.4%	1,580	-2.0%	1,526	15.5%
	PADCEV	219	25.9%	194	11.4%	199	11.3%	244	29.7%
	IZERVAY	110	35.0%	124	20.2%	141	31.9%	139	53.3%
	VYLOY	41	-	43	-	57	662.8%	57	134.3%
	VEOZAH	59	50.7%	81	62.0%	69	20.8%	61	8.4%
	XOSPATA	51	-11.3%	54	-9.5%	57	-8.8%	50	-0.4%
	XTANDI	848	10.4%	849	1.1%	836	-11.6%	675	0.6%
	MYRBETRIQ	107	-11.1%	104	163.4%	89	-28.8%	180	43.4%
	CRESEMBA	80	14.5%	92	19.1%	95	13.6%	95	20.4%

(2) Japan

Unit:B¥

		FY25							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		68.9	3.4%	74.0	10.7%	80.1	11.0%	65.9	7.6%
	PADCEV	5.1	102.3%	5.0	107.8%	5.7	52.5%	4.5	14.5%
	IZERVAY	-	-	-	-	0.0	-	0.1	-
	VYLOY	3.1	791.2%	3.3	274.4%	4.0	114.4%	3.3	58.0%
	XOSPATA	1.3	3.8%	1.2	7.2%	1.5	14.9%	1.0	1.1%
	XTANDI	15.9	7.1%	16.2	16.6%	17.7	13.7%	15.0	10.1%
	BETANIS	5.7	-14.3%	5.5	-7.1%	6.2	-8.0%	5.0	-8.1%
	PROGRAF (Including GRACEPTOR)	4.6	-27.4%	4.6	-18.2%	5.0	-2.1%	3.9	-3.0%
	SUGLAT [Family]	6.3	-10.2%	5.9	-9.3%	6.3	-12.1%	4.8	-16.7%
	BLINCYTO	3.5	8.2%	3.9	16.7%	4.7	17.5%	3.8	31.2%
	EVENITY	16.5	20.1%	17.8	30.1%	20.5	32.4%	19.4	29.8%

(3) Established Markets

Unit:ME

		FY25							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		786	8.9%	790	8.7%	856	12.5%	792	4.5%
	PADCEV	58	29.1%	62	35.4%	105	99.2%	74	29.9%
	VYLOY	10	-	16	-	19	356.3%	20	118.0%
	VEOZA	5	112.1%	7	62.5%	7	34.2%	8	78.3%
	XOSPATA	34	23.7%	34	23.2%	30	5.9%	34	6.1%
	XTANDI	424	8.3%	417	3.3%	423	3.7%	401	0.5%
	BETMIGA	102	10.4%	102	12.3%	114	15.1%	102	1.4%
	PROGRAF	113	-1.1%	114	2.0%	121	3.9%	111	-4.6%

- Established Markets: Europe, Canada, etc.

(4) China

Unit:B¥

		FY25							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		29.4	57.8%	20.3	6.8%	27.6	35.6%	24.1	19.0%
	PADCEV	7.4	-	-0.2	-	2.3	-	0.3	-92.2%
	VYLOY	3.3	-	-0.1	-	2.9	-	0.6	-
	XOSPATA	1.0	-26.6%	1.0	-41.3%	1.4	-11.0%	1.2	-
	XTANDI	4.8	58.3%	5.9	53.4%	6.6	55.4%	7.4	42.5%
	PROGRAF	10.4	-7.5%	11.2	4.7%	11.3	-1.5%	11.8	21.2%

- China: China, Hong Kong

(5) International Markets

Unit:B¥

		FY25							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		53.2	2.3%	58.3	21.5%	63.2	21.1%	56.0	9.2%
	PADCEV	1.8	62.6%	2.8	171.8%	2.7	54.1%	2.3	25.4%
	VYLOY	0.1	-	0.3	-	0.5	-	0.6	-
	VEOZA	0.1	861.7%	0.2	366.6%	0.3	258.9%	0.4	158.2%
	XOSPATA	1.7	57.0%	1.5	9.0%	2.0	55.8%	1.9	12.8%
	XTANDI	20.2	-3.2%	24.8	35.9%	26.1	23.4%	25.4	5.6%
	BETMIGA	5.0	1.3%	4.9	5.3%	5.6	16.2%	5.4	21.8%
	PROGRAF	14.9	3.7%	14.1	9.0%	14.9	9.4%	11.0	5.2%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Apr 2026

Underlined items indicate changes from the previous announcement in Feb 2026.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Cisplatin-ineligible muscle-invasive bladder cancer (combo with pembrolizumab)	Europe Filed (Nov 2025) Japan Filed (Jan 2026) NCT03924895	In-house [Co-development with Pfizer]	
			Cisplatin-eligible muscle-invasive bladder cancer (combo with pembrolizumab)	<u>Europe Filed (Mar 2026)</u> <u>US Filed (Apr 2026)</u> NCT04700124		
			<u>Bladder-sparing muscle-invasive bladder cancer (combo with pembrolizumab)</u>	<u>P-II</u> <u>NCT07475806</u>		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III NCT04027309	In-house	
			Post-chemotherapy maintenance acute myeloid leukemia	P-III		
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II NCT05520567		
			Acute myeloid leukemia in pediatric patients	P-III NCT04293562		
			ALK-positive non-small cell lung cancer	P-I NCT07140016		
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III NCT06901531	In-house (Ganymed)	

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensors **	Remarks
fezolinetant ESN364 (VEOZAH***)	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III NCT06812754 Japan P-III NCT06206408 NCT06206421	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III NCT06440967		

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Feb 2026):

enfortumab vedotin: Removed the description of approval in US for cisplatin-ineligible muscle-invasive bladder cancer in Nov 2025. Filed in Europe in Mar 2026 and US in Apr 2026 for cisplatin-eligible muscle-invasive bladder cancer. Entered into Phase 2 for bladder-sparing muscle-invasive bladder cancer.

Programs with Focus Area approach

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
Immunology	ASP2138	T-cell engager	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I NCT05365581 NCT07024615	Xencor [Discovered through collaborative research]	
	ASP1002	T-cell engager	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I NCT05719558	In-house	
	VIR-5500	T-cell engager	Anti-PSMA and anti-CD3 T-cell engager	Prostate cancer	P-I NCT05997615	Vir Biotechnology	
	ASP2998	Antibody-drug conjugate (ADC)	TROP2 targeted dual-payload iADC	Cancer	P-I NCT07287995	Sutro Biopharma [Discovered through collaborative research]	
Targeted Protein Degradation	setidegrasib	Small molecule	KRAS G12D degrader	Pancreatic ductal adenocarcinoma	P-III NCT07409272	In-house	
				Cancer	P-I NCT05382559		
	ASP5834	Small molecule	Pan-KRAS degrader	Cancer	P-I NCT07094204	In-house	
Genetic regulation	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-II NCT04174105	In-house (Audentes Therapeutics)	
	ASP2957	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-I NCT07052929	Kate Therapeutics/Novartis	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I NCT03178149	In-house (Ocata Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Feb 2026):

VIR-5500: Entered into Phase 1 for prostate cancer.

ASP2998: Entered into Phase 1 for cancer.

setidegrasib: Entered into Phase 3 for pancreatic ductal adenocarcinoma.

ASP2957: Entered into Phase 1 for X-linked myotubular myopathy.

ASP1570: Discontinued Phase 1 program for cancer.

AT132: Removed Phase 2 program for X-linked myotubular myopathy due to strategic halt.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III NCT05621616	In-house	
roxadustat ASP1517/FG-4592	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III NCT05970172	Kyntra Bio	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate ASP5541/PRL-02	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-II NCT07005154	In-house (Propella Therapeutics)	
ASP546C	Antibody-drug conjugate (ADC)	Claudin 18.2-targeted ADC	Cancer	P-I NCT07488676	Evopoint Biosciences	Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and Taiwan.

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Feb 2026):

ASP5502: Discontinued Phase 1 program for Primary Sjogren's syndrome.

Rx+ Program

As of Apr 2026

Category	Program	Concept	Status*	Partner	Remarks
Digital health	BlueStar	Digital therapeutic for the management of diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
Implantable medical device	Akyva	Implantable device for underactive bladder	Early feasibility study	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.